Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13,778 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study.
Crawford TO, Swoboda KJ, De Vivo DC, Bertini E, Hwu WL, Finkel RS, Kirschner J, Kuntz NL, Nazario AN, Parsons JA, Pechmann A, Ryan MM, Butterfield RJ, Topaloglu H, Ben-Omran T, Sansone VA, Jong YJ, Shu F, Zhu C, Raynaud S, Lago TR, Paradis AD, Foster R, Chin R, Berger Z; NURTURE Study Group. Crawford TO, et al. Among authors: raynaud s. Muscle Nerve. 2023 Aug;68(2):157-170. doi: 10.1002/mus.27853. Epub 2023 Jul 6. Muscle Nerve. 2023. PMID: 37409780
Long-Term Safety and Effectiveness of Dimethyl Fumarate in Patients with Multiple Sclerosis Treated in Routine Medical Practice: Final Analysis of the ESTEEM Study.
Pandey KS, Giles K, Balashov K, Macdonell R, Windsheimer J, Martinez M, Božin I, Raynaud S, Scaramozza M, Mokliatchouk O, Sun Z, Belviso N, Sato Y, Lin X, Okai A. Pandey KS, et al. Among authors: raynaud s. Neurol Ther. 2025 Feb;14(1):243-260. doi: 10.1007/s40120-024-00680-z. Epub 2024 Dec 14. Neurol Ther. 2025. PMID: 39673658 Free PMC article.
Validation and cross-cultural adaptation of the Thai version of the Systemic Sclerosis Health Assessment Questionnaire.
Ruangnopparut R, Osiri M, Suwannaroj S, Mahakkanukrauh A, Pongkulkiat P, Onchan T, Foocharoen C. Ruangnopparut R, et al. Clin Rheumatol. 2025 Jul 1. doi: 10.1007/s10067-025-07553-2. Online ahead of print. Clin Rheumatol. 2025. PMID: 40593370
METHOD: The six VAS items, which assess pain, gastrointestinal symptoms, respiratory symptoms, Raynaud's phenomenon (RP), digital ulcers (DU), and overall disease activity interfering with daily activities, were translated into Thai and validated. ...Addition …
METHOD: The six VAS items, which assess pain, gastrointestinal symptoms, respiratory symptoms, Raynaud's phenomenon (RP), digi …
New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025.
Sieiro Santos C, Del Galdo F. Sieiro Santos C, et al. RMD Open. 2025 Jul 1;11(3):e005776. doi: 10.1136/rmdopen-2025-005776. RMD Open. 2025. PMID: 40592721 Review.
Systemic sclerosis (SSc) is a rare, multisystem autoimmune disease characterised by vasculopathy, immune dysregulation, and progressive fibrosis, leading to significant morbidity and mortality. ...These innovations offer the potential to alter disease trajectory and …
Systemic sclerosis (SSc) is a rare, multisystem autoimmune disease characterised by vasculopathy, immune dysregulation, and progressi …
Trajectories of FEV1 after lung transplantation and patient outcomes.
Raynaud M, Belousova N, Glorion M, Hillebrand C, Picard C, Dhanani ZN, Beaumont-Azuar L, de Verdière SC, Sage É, Messika J, Bunel V, Tissot A, Levine D, Le Pavec J, Macey J, Coiffard B, Villeneuve T, Renaud-Picard B, Falque L, Carlier N, Merveilleux C, Anjum F, Magnan A, Benazzo A, Loupy A, Roux A. Raynaud M, et al. J Heart Lung Transplant. 2025 Jun 24:S1053-2498(25)02036-4. doi: 10.1016/j.healun.2025.06.011. Online ahead of print. J Heart Lung Transplant. 2025. PMID: 40592371
Patients belonging to trajectories were associated with gender (p=0.020) and underlying disease (p=0.004). Similar FEV(1) trajectories and patient outcomes were identified in the external validation cohorts on the basis of independent analyses. ...
Patients belonging to trajectories were associated with gender (p=0.020) and underlying disease (p=0.004). Similar FEV(1) trajectorie …
Correction: AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity.
Yap TA, Walton MI, Grimshaw KM, Te Poele RH, Eve PD, Valenti MR, de Haven Brandon AK, Martins V, Zetterlund A, Heaton SP, Heinzmann K, Jones PS, Feltell RE, Reule M, Woodhead SJ, Davies TG, Lyons JF, Raynaud FI, Eccles SA, Workman P, Thompson NT, Garrett MD. Yap TA, et al. Clin Cancer Res. 2025 Jul 1;31(13):2840. doi: 10.1158/1078-0432.CCR-25-1021. Clin Cancer Res. 2025. PMID: 40589262 No abstract available.
13,778 results
You have reached the last available page of results. Please see the User Guide for more information.